FDA Determines That Biomerica's Proposed InFoods(R) IBS Clinical Investigation Is a Nonsignificant Risk (NSR) Device Study
IRVINE, CA--(Marketwired - July 11, 2016) - Biomerica, Inc. (OTCQB: BMRA) announced today that the U.S. Food and Drug Administration (FDA) has determined that the proposed clinical study to validate performance of its InFoods® IBS product is a …